Vita Group Extended Its Telstra Dealer Agreement And Master License

Vita Group Ltd

On 12 December 2018, consultative solutions provider Vita Group Limited (ASX: VTG) announced that its Telstra Dealer Agreement and Master License has been extended and rolled on for a further year through to 30 June 2024. Following this news, the share price of the company decreased by 1.869 percent as on 12 December 2018.

As per Vita Group’s Chief Executive Officer (CEO) Maxine Horne, Vita’s team continues to deliver against Telstra’s performance expectations, and the company is focused on ensuring that its partnership remains strategically aligned and operationally strong.

She added further that Vita’s role is to support Telstra in achieving its strategic and performance objectives, including the delivery of their T22 plan. According to Ms. Maxine Horne, the extension of agreement shows Vita’s ability to consistently execute strongly in the market and it also shows a strong relationship between Telstra and Vita.

In FY 2018, Vita’s revenue increased by 3 percent to $684.5 million as compared to the previous corresponding period (pcp). The operating cost in FY 2018 decreased by 4 percent to $182.1 million as compared to pcp. The company reported an EBITDA of $41.0m and EBIT of $30.9m in FY 2018. In FY 2018, the company paid a fully-franked dividend of 9.1 cents per share.

For the first half of FY 2019, the company is expecting its EBITDA to be in the range of $23.0m – 24.5m which is 15% – 23% higher than 1H FY18. Further, the company is expecting EBIT to be around 18.0m – $19.4m in 1H FY19 which is 15% – 24% higher than 1H FY18.

In the company’s ICT channel, the company achieved strong device sales and solid improvement in store performance and productivity through its ongoing focus on embedding tools, systems, and processes for its consultants. Retail ICT revenues increased by 2% and small-to-medium business ICT revenues increased by 6%. The company’s strategy to discontinue lower returning lines of business in its enterprise channel resulted in higher relative profitability.

The company also made excellent progress towards its strategic goal of expanding its future revenue streams, with the entry into the billion-dollar non-invasive medical aesthetics (NIMA) category through the acquisition of seven clinics. Over the next five years, the company is planning to establish a national network of premium aesthetic clinics, under the brand of Artisan Aesthetic Clinics, with its first greenfield locations opening in the second quarter of FY19. As at 30 June 2018, Vita’s physical portfolio had 105 Telstra Licensed Stores, 23 Telstra Business Centres, one Fone Zone store, one SQD Athletica store, six Clear Complexions clinics, and one Artisan Cosmetic & Rejuvenation clinic.

In the last six months, the share price of the company increased by 5.94 percent as on 11 December 2018 and traded at a PE ratio of 7.570x. VTG’s shares traded at $1.050 with a market capitalization of circa $172.78 million as on 12 December 2018 (AEST 4:00 PM).


Disclaimer

This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.


6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report